Laura Lee Sandler - 02 Mar 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Role
Chief Operating Officer
Signature
/s/ Paul Quinlan, as attorney-in-fact for Laura Sandler
Issuer symbol
ORKA
Transactions as of
02 Mar 2026
Net transactions value
-$128,822
Form type
4
Filing time
02 Mar 2026, 18:47:50 UTC
Previous filing
23 Jan 2026
Next filing
17 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sandler Laura Lee Chief Operating Officer C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK /s/ Paul Quinlan, as attorney-in-fact for Laura Sandler 02 Mar 2026 0002075401

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORKA Common Stock Options Exercise $39,000 +5,000 +2.1% $7.80 242,584 02 Mar 2026 Direct
transaction ORKA Common Stock Sale $77,386 -2,325 -0.96% $33.28 240,259 02 Mar 2026 Direct F1, F2
transaction ORKA Common Stock Sale $90,436 -2,675 -1.1% $33.81 237,584 02 Mar 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORKA Employee Warrant (right to buy) Options Exercise $0 -5,000 -5.3% $0.000000 89,996 02 Mar 2026 Common Stock 5,000 $7.80 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $33.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.66 to $34.33, inclusive.
F4 The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.